Biogen's (NASDAQ:BIIB) decision to spend $300m to license in a phase I anti-tau antibody from Bristol-Myers Squibb (NYSE:BMY) shows that repeated failure seems to be no impediment to continued development of Alzheimer’s disease projects.
The deal brings to five the number of assets for the neurodegenerative condition held by the Massachusetts-based biotech, and its second project targeting tau deposits rather than amyloid plaques (see table below). Meanwhile, Bristol signalled its withdrawal from Alzheimer’s development, and in so doing, sold at a profit an agent it bought with Ipierian for $175m three years ago ("Development-stage M&A premiums reward very patient investors," May 7, 2014).

